Financial Architects (New Jersey)’s Neurocrine Biosciences NBIX Stock Holding History

Financial Architects (New Jersey)’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-17	Closed	-$1K	–	1114
2019 Q2	$1K	Sell	17 -968	-98%	-$79.5K	﹤0.01%	1145
2019 Q1	$86K	Sell	985 -117	-11%	-$9.78K	0.01%	497
2018 Q4	$78K	Sell	1,102 -283	-20%	-$27.1K	0.01%	458
2018 Q3	$170K	Buy	1,385 +1,024	+284%	+$116K	0.03%	343
2018 Q2	$35K	Buy	+361	New	+$32.3K	0.01%	659

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Architects (New Jersey)'s NBIX Position: Q3 2019 in Review

Financial Architects (New Jersey) sold out of Neurocrine Biosciences (NBIX) in Q3 2019, closing a stake of 17 shares — an estimated $1K sold.

Financial Architects (New Jersey) first reported a position in NBIX in Q2 2018 and held it in 5 quarters. The position peaked at $170K in Q3 2018. 332 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

Financial Architects (New Jersey) reported no remaining Neurocrine Biosciences position as of Q3 2019 after selling out during the quarter.
Financial Architects (New Jersey) sold 17 Neurocrine Biosciences shares in Q3 2019, an estimated $1K.
Financial Architects (New Jersey) first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 5 quarters.
Financial Architects (New Jersey)'s Neurocrine Biosciences position peaked at $170K in Q3 2018.
332 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Financial Architects (New Jersey)'s 13F filing for Q3 2019, filed 6 Nov 2019.